相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
Filippo Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2019)
Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1-2 and cN0 breast cancer
Hideo Shigematsu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer
Elisa M. Werner et al.
ANTICANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
Andreas Schneeweiss et al.
EUROPEAN JOURNAL OF CANCER (2018)
Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes
Julien Tanniou et al.
BMC MEDICAL RESEARCH METHODOLOGY (2016)
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Edgardo Rivera et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments
Claudia Omarini et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: An Integrated Safety Analysis
Veronique Dieras et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja et al.
LANCET ONCOLOGY (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET ONCOLOGY (2014)
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Marta Seretny et al.
PAIN (2014)
Interpreting and comparing risks in the presence of competing events
Martin Wolkewitz et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Bernhard C. Pestalozzi et al.
LANCET ONCOLOGY (2013)
Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic Chemotherapy Results from a Retrospective Hospital-Based Cohort
Maarten J. ten Berg et al.
DRUG SAFETY (2011)
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
